Recombinant Mouse Cannabinoid receptor 1 (Cnr1)

Code CSB-CF005678MO
Size Pls inquire
Source in vitro E.coli expression system
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Names
Cnr1
Uniprot No.
Alternative Names
Cnr1; Cannabinoid receptor 1; CB-R; CB1; Brain-type cannabinoid receptor
Species
Mus musculus (Mouse)
Expression Region
1-473
Target Protein Sequence
MKSILDGLADTTFRTITTDLLYVGSNDIQYEDIKGDMASKLGYFPQKFPLTSFRGSPFQE KMTAGDNSPLVPAGDTTNITEFYNKSLSSFKENEDNIQCGENFMDMECFMILNPSQQLAI AVLSLTLGTFTVLENLLVLCVILHSRSLRCRPSYHFIGSLAVADLLGSVIFVYSFVDFHV FHRKDSPNVFLFKLGGVTASFTASVGSLFLTAIDRYISIHRPLAYKRIVTRPKAVVAFCL MWTIAIVIAVLPLLGWNCKKLQSVCSDIFPLIDETYLMFWIGVTSVLLLFIVYAYMYILW KAHSHAVRMIQRGTQKSIIIHTSEDGKVQVTRPDQARMDIRLAKTLVLILVVLIICWGPL LAIMVYDVFGKMNKLIKTVFAFCSMLCLLNSTVNPIIYALRSKDLRHAFRSMFPSCEGTA QPLDNSMGDSDCLHKHANNTASMHRAAESCIKSTVKIAKVTMSVSTDTSAEAL
Protein Length
Full length protein
Tag Info
Tag type will be determined during the manufacturing process.
The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
Form
Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer before Lyophilization
Tris/PBS-based buffer, 6% Trehalose, pH 8.0
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet
Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
G-protein coupled receptor for cannabinoids, including endocannabinoids (eCBs), such as N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG). Mediates many cannabinoid-induced effects, acting, among others, on food intake, memory loss, gastrointestinal motility, catalepsy, ambulatory activity, anxiety, chronic pain. Signaling typically involves reduction in cyclic AMP. In the hypothalamus, may have a dual effect on mitochondrial respiration depending upon the agonist dose and possibly upon the cell type. Increases respiration at low doses, while decreases respiration at high doses. At high doses, CNR1 signal transduction involves G-protein alpha-i protein activation and subsequent inhibition of mitochondrial soluble adenylate cyclase, decrease in cyclic AMP concentration, inhibition of protein kinase A (PKA)-dependent phosphorylation of specific subunits of the mitochondrial electron transport system, including NDUFS2. In the hypothalamus, inhibits leptin-induced reactive oxygen species (ROS) formation and mediates cannabinoid-induced increase in SREBF1 and FASN gene expression. In response to cannabinoids, drives the release of orexigenic beta-endorphin, but not that of melanocyte-stimulating hormone alpha/alpha-MSH, from hypothalamic POMC neurons, hence promoting food intake. In the hippocampus, regulates cellular respiration and energy production in response to cannabinoids. Involved in cannabinoid-dependent depolarization-induced suppression of inhibition (DSI), a process in which depolarization of CA1 postsynaptic pyramidal neurons mobilizes eCBs, which retrogradely activate presynaptic CB1 receptors, transiently decreasing GABAergic inhibitory neurotransmission. Also reduces excitatory synaptic transmission. In superior cervical ganglions and cerebral vascular smooth muscle cells, inhibits voltage-gated Ca(2+) channels in a constitutive, as well as agonist-dependent manner. In cerebral vascular smooth muscle cells, cannabinoid-induced inhibition of voltage-gated Ca(2+) channels leads to vasodilation and decreased vascular tone. Induces leptin production in adipocytes and reduces LRP2-mediated leptin clearance in the kidney, hence participating in hyperleptinemia. In adipose tissue, CNR1 signaling leads to increased expression of SREBF1, ACACA and FASN genes. In the liver, activation by endocannabinoids leads to increased de novo lipogenesis and reduced fatty acid catabolism, associated with increased expression of SREBF1/SREBP-1, GCK, ACACA, ACACB and FASN genes. May also affect de novo cholesterol synthesis and HDL-cholesteryl ether uptake. Peripherally modulates energy metabolism. In high carbohydrate diet-induced obesity, may decrease the expression of mitochondrial dihydrolipoyl dehydrogenase/DLD in striated muscles, as well as that of selected glucose/ pyruvate metabolic enzymes, hence affecting energy expenditure through mitochondrial metabolism. In response to cannabinoid anandamide, elicits a proinflammatory response in macrophages, which involves NLRP3 inflammasome activation and IL1B and IL18 secretion. In macrophages infiltrating pancreatic islets, this process may participate in the progression of type-2 diabetes and associated loss of pancreatic beta-cells.
Gene References into Functions
  1. Taste bud cells from CBR(-/-) mice also exhibited decreased Proglucagon and Glp-1r mRNA and a low GLP-1 basal level. We report that CBR is involved in fat taste perception via calcium signaling and GLP-1 secretion. PMID: 30241419
  2. CNR1 deficiency attenuates insulin resistance and endoplasmic reticulum stress in heart of mice fed with high fat diet. PMID: 29909009
  3. Results show that the subcellular CB1 receptor distribution in astrocytes in mice expressing CB1 receptors only in astrocytes completely matches the endogenous CB1 receptor expression and localization in astrocytes of the wild-type mouse hippocampus. Moreover, findings illustrate localization of CB1 receptors in astroglial mitochondria. PMID: 29480581
  4. Results suggest that CB1R located on corticostriatal projections, by inhibiting glutamatergic transmission, protects dopamine D1 recpetor-medium spiny neurons not only from cortical mutant tHtt-evoked damage, as shown above, but also from astroglial mutant tHtt-evoked damage. PMID: 29121220
  5. Results showed sensitivity of activated microglial cells to cannabinoids, increased CB1-CB2Het expression in activated microglia and in microglia from the hippocampus of an Alzheimer's model, and a correlation between levodopa-induced dyskinesia and striatal microglial activation in a Parkinson's disease model. PMID: 28843453
  6. Study revealed distinct degrees of modulation for different emotional behaviors by the GABAergic population of cannabinoid CB1 receptors. PMID: 28393261
  7. Combined deficiency of the Cnr1 and Cnr2 receptors protects against age-related bone loss by osteoclast inhibition. PMID: 28752643
  8. Results show increased locomotor activity only in hypothyroid CB1R+/+ mice which is absent in those animals lacking this receptor, suggesting that the CB1R gene is essential for the establishment of the hyperlocomotor phenotype in hypothyroid animals. In parallel, a decreased response to haloperidol was observed only in hypothyroid CB1R+/+ mice, which may reflect an alteration in the dopamine D2 receptor (D2R) pathway. PMID: 28017790
  9. The purpose of the studies in this report was to begin to explore the role of endocannabinoid signaling in Operant sensation seeking utilizing cannabinoid receptor 1 (CB1R) and fatty acid amide hydrolase (FAAH) knock out mice. PMID: 28749428
  10. Data show that systemic, hippocampal, and peripheral blockade of cannabinoid type-1 (CB1) receptors abolished the stress-induced memory impairment. PMID: 27528659
  11. this study shows that genetic or pharmacological depletion of cannabinoid CB1 receptor protects against dopaminergic neurotoxicity induced by methamphetamine in mice PMID: 28363605
  12. CB1R knockout mice demonstrated increased injury following stroke, indicating that activation of the CB1R was neuroprotective, later studies of selective antagonists of the CB1R also demonstrated a protective effect PMID: 29288767
  13. Findings demonstrate a critical distinction of the altered balance of glutamate-type 1 cannabinoid receptor and GABA-type 1 cannabinoid receptor activity that could participate in the vulnerability to cocaine abuse and addiction. PMID: 26612422
  14. renal proximal tubule cell CB1R contributes to the pathogenesis of obesity-induced renal lipotoxicity and nephropathy by regulating the liver kinase B1/AMP-activated protein kinase signaling pathway PMID: 28860163
  15. a protein involved in macroautophagy/autophagy (a conserved lysosomal degradation pathway), BECN2 (beclin 2), mediates cannabinoid tolerance by preventing CNR1 recycling and resensitization after prolonged agonist exposure, and deletion of Becn2 rescues CNR1 activity in mouse brain and conveys resistance to analgesic tolerance to chronic cannabinoids PMID: 27305347
  16. N-arachidonoyl ethanolamine and 2-arachidonoyl glycerol hydrolyzing enzymes, FAAH and MAGL, and the CB1 receptor link the endocannabinoid system to broader lipid signaling networks in contrasting ways, potentially altering neurotransmission and behavior independently of cannabinoid receptor signaling. PMID: 27109320
  17. Given overlapping and complementary functions of CB1 and CB2 receptors, we queried whether double-knockout mice would show an exacerbated neurological phenotype PMID: 29105060
  18. this study shows that the expression of CB1 receptor in B-lymphocytes is differentially regulated during pregnancy PMID: 27163857
  19. Loss of adipocyte CB1 affects energy balance by promoting a profound remodeling in depot-specific adipocyte functions. PMID: 29035280
  20. mtCB1 quickly upregulated after traumatic brain injury. PMID: 27485212
  21. mGluR5 and CB1 act in concert to activate neuroprotective cell signaling pathways and promote neuronal survival. PMID: 27543109
  22. Salicylate-induced tinnitus may be associated with increased mRNA expression of the DR1A gene - but with decreased mRNA expression of the CR1 gene - in the cochlea and in many tinnitus-related brain areas. PMID: 27658122
  23. analysis of the composition and differences of CB1 protein complexes in glutamatergic neurons and in GABAergic interneurons in hippocampal mouse tissue by proteomics PMID: 27596989
  24. Identification of mouse CB1 receptor splice variants may help to explain differences found between human and mouse endocannabinoid systems and improve the understanding of CB1 receptor signaling and trafficking in different species PMID: 28608535
  25. our results reveal that ERRgamma, induced via activation of the hepatic CB1 receptor, is a regulator of hepatic FGF21 gene expression and secretion. PMID: 27455076
  26. Morphine-induced conditioned place preference (CPP) elevated Cannabinoid CB1 receptor (CB1R) expression both in the nucleus accumbens and hippocampus. AM251 attenuated morphine-induced CPP and CB1R expression in the NAc and Hippocampus. CB1R mediated downstream ERK-CREB-BDNF signaling is implicated in morphine reward. PMID: 27461790
  27. A bidirectional link was found between the CB1 receptor and microRNA let-7d involved in the regulation of cannabinoid signaling. PMID: 27179908
  28. Study investigated the impact of the CB1 receptor ligands on the symptoms typical for schizophrenia. Antipsychotic-like effects induced by CB1 receptor antagonist, obtained in our research, confirm the potential effect of CB1 receptor blockade and could have important therapeutic implications on clinical settings, in the future. PMID: 27577742
  29. CB1 activation enhances protein synthesis via the mTOR pathway, resulting in long-term depression of inhibitory transmission in GABA-ergic presynaptic interneuron axons. PMID: 27764673
  30. Decreased expression of CB1 receptor was found in the cingulate cortex of animals exposed to chronic unpredictable stress. PMID: 27737789
  31. CB1 involvement in the posttraumatic stress disorder-alcohol interaction PMID: 27186643
  32. Deletion of cannabinoid type 1 (CB1) receptors from cortical projections originating in the orbital frontal cortex (OFC) prevents mice from shifting from goal-directed to habitual instrumental lever pressing. PMID: 27238866
  33. Study demonstrated that activation of the OX1 receptor in the ventrolateral periaqueductal gray of mice can initiate an endocannabinoid-CB1 receptor-mediated analgesia. Activation of the OX2 receptor in the ventrolateral periaqueductal gray was also antinociceptive but this antinociceptive effect is CB1 receptor-independent. PMID: 26907809
  34. This study demonstrated that CB1 receptor mediated respiratory depression by endocannabinoids. PMID: 28254562
  35. there was a significant reduction in CB1 receptor gene expression levels in cancer tissue compared to normal surrounding mucosa of patients with CRC, confirming that in cancer the "protective" action of the CB1 receptor is lost. PMID: 28245562
  36. CB1 receptor tolerance does not occur in aged mice pretreated with Delta(9)-tetrahydrocannabinol and in young adult mice treated with a low dose of the monoacylglycerol lipase inhibitor JZL 184. PMID: 26984820
  37. CB1R expression contributes to the development of persistent mechanical hypersensitivity. PMID: 27206660
  38. Findings suggest a minor role for the CB2 receptor in the therapeutic effect of the cannabis-based medicine in AbetaPP/PS1 transgenic mice, but also constitute evidence of a link between CB2 receptor and Abeta processing PMID: 26890764
  39. Suggest that the CB1R is involved in auditory processing using CB1R knockout mice. PMID: 26427583
  40. CB1 activation negatively impacts GLP-1R-mediated insulin secretion. PMID: 26724516
  41. Study showed that basolateral amygdala alpha2-adrenergic receptors may be involved in context- but not tone-dependent fear memory impairment induced by activation of CB1 receptors PMID: 26698395
  42. Adult female Cnr1 knockouts do not exhibit increased anxiety as in adult male Cnr1 knockouts; adult female ovariectomy does not increase anxiety-like behavior in Cnr1 knockouts; Cnr1 antagonism increases anxiety-like behavior in C57BL/6J mice PMID: 26684509
  43. Results provide clear evidence that the endocannabinoid system, through CB1 receptors, participates in the different stages of short- and long-term memory-related behavior PMID: 26711911
  44. CB1 receptor and mTORC1 signalling pathways interact to modulate glucose homeostasis in mice PMID: 26563389
  45. cannabidiol causes vasorelaxation of human mesenteric arteries via activation of cannabinoid receptor 1 PMID: 26092099
  46. These results demonstrate that the CB1R-Ih pathway in the hippocampus is obligatory for the action of cannabinoids on long-term potentiation and spatial memory formation. PMID: 26898775
  47. Study showed a pivotal role of CB1r in the regulation of sensorimotor gating processes and demonstrated that the preattentional deficit showed by CB1KO mice could be improved by methylphenidate but not with haloperidol or risperidone administration PMID: 25895455
  48. The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway. PMID: 25698444
  49. CB1 has a major role in the activation of myofibroblasts. PMID: 25760323
  50. Constantly elevated levels of 2-arachidonyl glycerol induce severe desensitization of intestinal CB1 receptors. PMID: 26075589

Show More

Hide All

Involvement in disease
May contribute to the development of diet-induced obesity and several obesity-associated features, such as dyslipidemia and liver steatosis, regulating peripheral lipogenesis, energy expenditure and feeding behavior. In the liver, mediates cannabinoid-induced de novo lipogenesis and reduces fatty acid catabolism (PubMed:15864349, PubMed:21987372). In muscles, affects energy expenditure through mitochondrial metabolism (PubMed:22841573, PubMed:26671069). Induces leptin production by adipocytes and reduces LRP2-mediated leptin clearance in the kidney. The resulting hyperleptinemia causes resistance to the anorexic and weight-reducing effects of leptin (PubMed:22841573). In response to cannabinoids, drives the release of orexigenic beta-endorphin from hypothalamic POMC neurons, hence promoting food intake (PubMed:25707796). The use of peripherally-restricted inverse agonists in diet-induced obese mice reduces appetite, body weight, hepatic steatosis, and insulin resistance (PubMed:22841573).
Subcellular Location
Cell membrane; Multi-pass membrane protein. Mitochondrion outer membrane. Cell projection, axon. Cell junction, synapse, presynapse.
Protein Families
G-protein coupled receptor 1 family
Tissue Specificity
Expressed in brain neurons (at protein level). Detected throughout the striatum, cortex and hippocampus, with highest levels in the lateral striatum. In rostral brain regions, high expression levels in the dorsal lateral striatum, while in the caudal brai
Database Links
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1